Savara Inc. (SVRA)
NASDAQ: SVRA · Real-Time Price · USD
3.460
-0.110 (-3.08%)
Oct 22, 2024, 4:00 PM EDT - Market closed
Company Description
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases.
The company’s lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis.
Savara Inc. is headquartered in Langhorne, Pennsylvania.
Savara Inc.
| Country | United States |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 37 |
| CEO | Matthew Pauls |
Contact Details
Address: 1717 Langhorne Newtown Road, Suite 300 Langhorne, Pennsylvania 19047 United States | |
| Phone | 512 614 1848 |
| Website | savarapharma.com |
Stock Details
| Ticker Symbol | SVRA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001160308 |
| CUSIP Number | 805111101 |
| ISIN Number | US8051111016 |
| Employer ID | 84-1318182 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Matthew Pauls J.D., M.B.A. | Chairman and Chief Executive Officer |
| David L. Lowrance CPA | Chief Financial Officer, Chief Administrative Officer and Secretary |
| Robert Lutz M.B.A. | Chief Operating Officer |
| Kate McCabe J.D. | Senior Vice President and General Counsel |
| Anne Erickson | Chief Business Officer |
| Brian Maurer | Head of Clinical Operations |
| Charles LaPree | Senior Vice President of Global Regulatory Affairs and Quality Assurance |
| Dr. Peter Clarke Ph.D. | Executive Vice President of Global Technical Operations |
| Dr. Raymond Dennis Pratt FACP, M.D. | Chief Medical Officer |
| Scott L. Wilhoit | Executive Vice President of Global Commercial |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 1, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Aug 14, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Aug 12, 2024 | 10-Q | Quarterly Report |
| Jul 26, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Jul 8, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Jun 28, 2024 | 8-K | Current Report |
| Jun 28, 2024 | 424B5 | Filing |
| Jun 26, 2024 | 8-K | Current Report |
| Jun 10, 2024 | 8-K/A | [Amend] Current report |
| Jun 7, 2024 | 8-K | Current Report |